Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted
Source: SeekingAlpha
2025-06-09 17:51:57 ET
What Happened
On April 30, 2025, Immunic, Inc. (IMUX) provided a readout from its CALLIPER study investigating Vidofludimus Calcium in progressive MS. Following the readout, the stock tanked more than 20%. The stock has continued to falter since the readout, especially after Immunic announced a capital raise on May 29, 2025. For reasons we will discuss, we believe the drop in stock price is unwarranted. We reiterate our Strong Buy rating....
Read the full article on Seeking Alpha
For further details see:
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted
Immunic Inc.
NASDAQ: IMUX
IMUX Trading
-15.16% G/L:
$1.175 Last:
4,026,747 Volume:
$1.39 Open:
IMUX Latest News
March 10, 2026 06:30:00 am
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
February 26, 2026 06:30:00 am
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
February 17, 2026 04:05:00 pm
Immunic Announces Closing of Oversubscribed Private Placement Financing
IMUX Stock Data
$99,716,036
88,288,987
2.21%
24
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
